Posted by Michael Wonder on 16 Nov 2021
Nexviazyme (avalglucosidase alfa for injection) is now approved in Canada for patients with late-onset Pompe disease (acid α-glucosidase deficiency)
15 November 2021 - Nexviazyme (avalglucosidase alfa for injection) is now approved in Canada for the long-term treatment of patients older than 6 months of age with late-onset Pompe disease (acid α-glucosidase deficiency).
Nexviazyme is an enzyme replacement therapy designed to provide an exogenous source of acid α-glucosidase to the body to drive cellular enzyme uptake and enhance glycogen clearance in target tissues.
